Xanthine oxidase inhibition alleviates the cardiac complications of insulin resistance: Effect on low grade inflammation and the angiotensin system

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  El Bassossy, Hany M ^a,b   Watson, Malcolm L ^c  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b Zagazig University   (Egypt)

^c University of Bath   (United Kingdom)

Author keywords

Allopurinol; Heart; Hypertension; Metabolic syndrome; Xanthine oxidase

Indexed keywords

8 ISOPROSTANE; ALLOPURINOL; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ISOPRENALINE; LACTATE DEHYDROGENASE; TUMOR NECROSIS FACTOR ALPHA; URIC ACID; XANTHINE OXIDASE; ENZYME INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOHYDRATE DIET; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; DRUG EFFECT; DYSLIPIDEMIA; ELECTROCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; HEART HEMODYNAMICS; HEART LEFT VENTRICLE RELAXATION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HYPERINSULINEMIA; HYPERURICEMIA; IMMUNOFLUORESCENCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LACTATE DEHYDROGENASE BLOOD LEVEL; LIPID DIET; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QTC INTERVAL; RAT; T-PEAK TO T-END; URIC ACID BLOOD LEVEL; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIAC MUSCLE; DIAGNOSTIC IMAGING; DRUG EFFECTS; ECHOGRAPHY; HEMODYNAMICS; INFLAMMATION; METABOLISM; ORAL DRUG ADMINISTRATION; OXIDATIVE STRESS; PATHOLOGY; WISTAR RAT;

ADMINISTRATION, ORAL; ALLOPURINOL; ANGIOTENSIN II; ANIMALS; DIET, HIGH-FAT; ELECTROCARDIOGRAPHY; ENZYME INHIBITORS; HEMODYNAMICS; INFLAMMATION; INSULIN RESISTANCE; ISOPROTERENOL; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIUM; OXIDATIVE STRESS; RATS, WISTAR; ULTRASONOGRAPHY; URIC ACID; XANTHINE OXIDASE;

EID: 84928721373     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0445-9     Document Type: Article

References (39)

1. Kolovou GD, Anagnostopoulou KK, Cokkinos DV. Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad Med J. 2005;81:358-66.
2. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among us adults: findings from the third national health and nutrition examination survey. JAMA. 2002;287:356-9.
3. Johnson RJ, Nakagawa T, Sanchez-Lozada LG, Shafiu M, Sundaram S, Le M, et al. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes. 2013;62:3307-15.
4. Filiopoulos V, Hadjiyannakos D, Vlassopoulos D. New insights into uric acid effects on the progression and prognosis of chronic kidney disease. Renal Fail. 2012;34:510-20.
5. El-Bassossy HM, El-Fawal R, Fahmy A, Watson ML. Arginase inhibition alleviates hypertension in the metabolic syndrome. Br J Pharmacol. 2013;169:693-703.
6. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58:87-114.
7. Struthers A, Shearer F. Allopurinol: novel indications in cardiovascular disease. Heart. 2012;98:1543-5.
8. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG. Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol. 2010;160:1577-9.
9. Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2006;290:F625-31.
10. El-Bassossy H, Dsokey N, Fahmy A. Characterization of vascular complications in experimental model of fructose induced metabolic syndrome. Toxicol Mech Meth. 2014;29:1-8.
11. Field KJ, White WJ, Lang CM. Anaesthetic effects of chloral hydrate, pentobarbitone and urethane in adult male rats. Lab Anim. 1993;27:258-69.
12. Yamamoto S, Matsui K, Sasabe M, Kitano M, Ohashi N. Effect of SMP-300, a new Na+/H+ exchange inhibitor, on myocardial ischemia and experimental angina models in rats. Jpn J Pharmacol. 2000;84:196-205.
13. Azhar A, El-Bassossy HM. Pentoxifylline alleviates cardiac ischemia and dysfunction following experimental angina in insulin resistance. PLoS ONE. 2014;9:e98281.
14. Mori T, Ishigai Y, Fukuzawa A, Chiba K, Shibano T. Pharmacological profile of semotiadil fumarate, a novel calcium antagonist, in rat experimental angina model. Br J Pharmacol. 1995;116:1668-72.
15. Hassan N, El-Bassossy HM, Zakaria MNM. Heme oxygenase-1 induction protects against hypertension associated with diabetes: Effect on exaggerated vascular contractility. Naunyn Schmiedebergs Arch Pharmacol. 2013;386:217-26.
16. Hassan NA, El-Bassossy HM, Mahmoud MF, Fahmy A. Caffeic acid phenethyl ester, a 5-lipoxygenase enzyme inhibitor, alleviates diabetic atherosclerotic manifestations: Effect on vascular reactivity and stiffness. Chem Biol Interact. 2014;213:28-36.
17. Mahmoud MF, Hassan NA, El Bassossy HM, Fahmy A. Quercetin protects against diabetes-induced exaggerated vasoconstriction in rats: effect on low grade inflammation. PLoS ONE. 2013;8:e63784.
18. Schafer S, Huber J, Wihler C, Rutten H, Busch AE, Linz W. Impaired left ventricular relaxation in type 2 diabetic rats is related to myocardial accumulation of N-(carboxymethyl)lysine. Eur J Heart Fail. 2006;8:2-6.
19. Loganathan R, Bilgen M, Al-Hafez B, Alenezy MD, Smirnova IV. Cardiac dysfunction in the diabetic rat: quantitative evaluation using high resolution magnetic resonance imaging. Cardiovas Diabetol. 2006;4:5-7.
20. Radovits T, Korkmaz S, Loganathan S, Barnucz E, Bomicke T, Arif R, et al. Comparative investigation of the left ventricular pressure-volume relationship in rat models of type 1 and type 2 diabetes mellitus. Am J Physiol - Heart Cir Physiol. 2009;297:H125-33.
21. Vergeade A, Mulder P, Vendeville C, Ventura-Clapier R, Thuillez C, Monteil C. Xanthine oxidase contributes to mitochondrial ROS generation in an experimental model of cocaine-induced diastolic dysfunction. J Cardiovasc Pharmacol. 2012;60:538-43.
22. van Noord C, Eijgelsheim M, Stricker BH. Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol. 2010;70:16-23.
23. Miki T, Tobisawa T, Sato T, Tanno M, Yano T, Akasaka H, et al. Does glycemic control reverse dispersion of ventricular repolarization in type 2 diabetes? Cardiovasc Diabetol. 2014;13:125.
24. Lu Z, Ji A, Taunton J, Lu Y, Shishido T, McClain C, et al. Reactive oxygen species-induced activation of p90 ribosomal s6 kinase prolongs cardiac repolarization via inhibiting outward K(+) channel activity. Circ Res. 2008;103:269-78.
25. Wagner S, RuffHM, Weber SL, Bellmann S, Sowa T, Schulte T, et al. ROS-activated Ca/calmodulin kinase II is required for late I(Na) augmentation leading to cellular Na and Ca overload. Circ Res. 2011;108:555-65.
26. Williams IL, Vazir A, Zaman AG. Review: the management of stable angina in diabetes. Br J Diab Vasc Dis. 2003;3:18-25.
27. Stone PH. Allopurinol: a new anti-ischemic role for an old drug. J Am Coll Cardiol. 2011;58:829-30.
28. Kanbay M, Segal M, Afsar B, Kang DH, Rodriguez-Iturbe B, Johnson RJ. The role of uric acid in the pathogenesis of human cardiovascular disease. Heart. 2013;99:759-66.
29. Heinig M, Johnson RJ. Role of uric acid in hypertension, renal disease, and metabolic syndrome. Cleve Clin J Med. 2006;73:1059-64.
30. Pickup JC. Inflammation and Activated Innate Immunity in the Pathogenesis of Type 2 Diabetes. Diabetes Care. 2004;27:813-23.
31. Riegersperger M, Covic A, Goldsmith D. Allopurinol, uric acid, and oxidative stress in cardiorenal disease. Inter Urol Nephrol. 2011;43:441-9.
32. Gliemann L, Nyberg M, Hellsten Y. Nitric oxide and reactive oxygen species in limb vascular function: What is the effect of physical activity? Free Rad Res. 2014;48:71-83.
33. Azhar A, El Bassossy HM. Pentoxifylline alleviates hypertension in metabolic syndrome: effect on low-grade inflammation and angiotensin system. J Endocrinol Invest. 2014. doi:10.1007/s40618-014-0209-z
34. El-Bassossy HM, El-Moselhy MA, Mahmoud MF. Pentoxifylline alleviates vascular impairment in insulin resistance via TNF-aα inhibition. Naunyn Schmiedebergs Arch Pharmacol. 2011;384:277-85.
35. Demirel U, Yalniz M, Aygün C, Orhan C, Tuzcu M, Sahin K, et al. Allopurinol ameliorates thioacetamide-induced acute liver failure by regulating cellular redox-sensitive transcription factors in rats. Inflammation. 2012;35:1549-57.
36. Frigolet ME, Torres N, Tovar AR. The renin-angiotensin system in adipose tissue and its metabolic consequences during obesity. J Nutr Biochem. 2013;24:2003-15.
37. Jia N, Dong P, Ye Y, Qian C, Dai Q. Allopurinol attenuates oxidative stress and cardiac fibrosis in angiotensin ii-induced cardiac diastolic dysfunction. Cardiovas Ther. 2012;30:117-23.
38. Robins SJ, Rubins HB, Faas FH, Schaefer EJ, Elam MB, Anderson JW, et al. Insulin resistance and cardiovascular events with low HDL cholesterol: the veterans affairs HDL intervention trial (VA-HIT). Diabetes Care. 2003;26:1513-7.
39. Wang W, Wang C, Ding XQ, Pan Y, Gu TT, Wang MX, et al. Quercetin and allopurinol reduce liver thioredoxin-interacting protein to alleviate inflammation and lipid accumulation in diabetic rats. Br J Pharmacol. 2013;169:1352-71.